NZ595528A - Sparc angiogenic domain and methods of use - Google Patents

Sparc angiogenic domain and methods of use

Info

Publication number
NZ595528A
NZ595528A NZ595528A NZ59552810A NZ595528A NZ 595528 A NZ595528 A NZ 595528A NZ 595528 A NZ595528 A NZ 595528A NZ 59552810 A NZ59552810 A NZ 59552810A NZ 595528 A NZ595528 A NZ 595528A
Authority
NZ
New Zealand
Prior art keywords
methods
angiogenic domain
sparc angiogenic
sparc
domain
Prior art date
Application number
NZ595528A
Other languages
English (en)
Inventor
Vuong Trieu
Daniel Knauer
Neil Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of NZ595528A publication Critical patent/NZ595528A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ595528A 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use NZ595528A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15932209P 2009-03-11 2009-03-11
PCT/US2010/027041 WO2010105097A2 (en) 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use

Publications (1)

Publication Number Publication Date
NZ595528A true NZ595528A (en) 2013-10-25

Family

ID=42729116

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595528A NZ595528A (en) 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use

Country Status (13)

Country Link
US (2) US20120087910A1 (enExample)
EP (1) EP2405932A4 (enExample)
JP (1) JP2012520081A (enExample)
KR (2) KR20110139256A (enExample)
CN (2) CN103724417A (enExample)
AU (1) AU2010224031B2 (enExample)
BR (1) BRPI1009457A2 (enExample)
CA (1) CA2755109A1 (enExample)
IL (2) IL215089A0 (enExample)
MX (1) MX2011009478A (enExample)
NZ (1) NZ595528A (enExample)
WO (1) WO2010105097A2 (enExample)
ZA (1) ZA201107415B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011224154A1 (en) * 2010-03-11 2012-09-27 Abraxis Bioscience, Llc SPARC angiogenic domain and methods of use
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN120361186A (zh) * 2025-04-15 2025-07-25 北京大学口腔医学院 一种促进血管生成和组织再生的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000677A1 (en) * 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
JP5590882B2 (ja) * 2006-06-26 2014-09-17 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 化学療法増感剤としてのシステインに富む酸性分泌タンパク質（ｓｐａｒｃ）
AU2008240117B2 (en) * 2007-04-13 2013-12-05 Abraxis Bioscience, Llc SPARC and methods of use thereof

Also Published As

Publication number Publication date
MX2011009478A (es) 2011-11-18
KR20110139256A (ko) 2011-12-28
CN103724417A (zh) 2014-04-16
AU2010224031B2 (en) 2013-05-02
JP2012520081A (ja) 2012-09-06
EP2405932A2 (en) 2012-01-18
US20140094416A1 (en) 2014-04-03
IL228795A0 (en) 2013-12-31
WO2010105097A2 (en) 2010-09-16
IL215089A0 (en) 2011-11-30
WO2010105097A8 (en) 2011-05-26
AU2010224031A2 (en) 2011-10-20
US20120087910A1 (en) 2012-04-12
BRPI1009457A2 (pt) 2016-03-01
CN102482334A (zh) 2012-05-30
EP2405932A4 (en) 2012-08-22
ZA201107415B (en) 2012-06-27
WO2010105097A3 (en) 2010-11-04
KR20130043242A (ko) 2013-04-29
CA2755109A1 (en) 2010-09-16
AU2010224031A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
NZ595528A (en) Sparc angiogenic domain and methods of use
NZ703378A (en) Degradable clostridial toxins
PH12017500930A1 (en) Hsp90 inhibitor combinations
CR11504A (es) Deteccion mejorada de la expresion de mage-a
NZ600205A (en) Selective exosite inhibition of papp-a activity against igfbp-4
NZ587652A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
NZ598650A (en) Dll4-binding molecules
NZ600731A (en) Oxyntomodulin peptide analogue
NZ600732A (en) Oxyntomodulin peptide analogue
NZ598466A (en) Catalytic domains from lysyl oxidase and loxl2
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
PH12013500714A1 (en) Anticancer fusion protein
UA105520C2 (uk) Антитіла до людського tweak та їхнє застосування
WO2010144231A3 (en) Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
IN2012DN05886A (enExample)
SG10201407036YA (en) Markers of Endothelial Progenitor Cells and Uses Thereof
WO2007106792A3 (en) Methods for treating sarcopenia with a growth hormone secretagogue
WO2007107748A3 (en) Inhibition of tumour growth
MY160754A (en) A method for detection of human papillomavirus (hpv) type
MX2011012531A (es) Combinacion terapeutica que comprende un tensioactivo pulmonar y un esteroide.
NZ595271A (en) Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
MX2009002935A (es) Metodo in vitro para la deteccion de candida glabrata, kit de diagnostico y usos de los mismo.
WO2008103966A3 (en) Compositions and methods using toll-like receptors and unc93b
MX2012005411A (es) Induccion de apomixis en las plantas cultivadas de reproduccion sexual y uso para la produccion de plantas total o parcialmente apomicticas.
EP2129359A4 (en) GPCR1 35 OR GPCR1 ANTAGONIST CHIMERIC PEPTIDE 42

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 MAR 2017 BY COMPUTER PACKAGES INC

Effective date: 20140328

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170218

LAPS Patent lapsed